PRX-08066 Maleic acid |
| Catalog No.GC16788 |
5-HT2B receptor antagonist,potent and selective
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 866206-55-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
PRX-08066 Maleic acid is a selective 5-hydroxytryptamine receptor 2B (5-HT2BR) antagonist [1].
5-HT receptors are a group of G protein-coupled receptors and play an important role in schizophrenia, feeding disorders, perception, depression, migraines, hypertension, anxiety, hallucinogens, and gastrointestinal dysfunctions.
In NET cell line, KRJ-I, PRX-08066 inhibited 5-HT secretion and cell proliferation and decreased ERK1/2 phosphorylation and profibrotic growth factor synthesis and secretion (TGFβ1, CTGF and FGF2). In the KRJ-I:HEK293 coculture system, PRX-08066 significantly reduced 5-HT release, Ki67, CTGF, TGFβ1 and FGF2 transcription in the KRJ-I cell line. 5-HT itself stimulated HEK293 proliferation [2].
PRX-08066 has preclinical safety profile, good bioavailability, and low acute toxicity, which is under phase II clinical trials for the treatment of hypoxia-induced pulmonary hypertension syndromes and pulmonary hypertension [3].
In the monocrotaline (MCT)-induced PAH male rats model, PRX-08066 (100 mg/kg) significantly increased right ventricular ejection fraction and reduced peak PA pressure at 50 and 100 mg/kg. Morphometric assessment of pulmonary arterioles showed PRX-08066 significantly reduced medial wall thickening, lumen occlusion and RV hypertrophy. Also, PRX-08066 diminished pulmonary vascular remodeling [1].
References:
[1]. Porvasnik SL, Germain S, Embury J, et al. PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats. J Pharmacol Exp Ther, 2010, 334(2): 364-372.
[2]. Svejda B, Kidd M, Giovinazzo F, et al. The 5-HT(2B) receptor plays a key regulatory role in both neuroendocrine tumor cell proliferation and the modulation of the fibroblast component of the neoplastic microenvironment. Cance, 2010, 116(12): 2902-2912.
[3]. Kim SK, Li Y, Abrol R, et al. Predicted structures and dynamics for agonists and antagonists bound to serotonin 5-HT2B and 5-HT2C receptors. J Chem Inf Model, 2011, 51(2): 420-433.
| Cas No. | 866206-55-5 | SDF | |
| Canonical SMILES | FC(C=C1)=C(C#N)C=C1CN(CC2)CCC2NC3=C(C=C(Cl)S4)C4=NC=N3.O=C(O)/C=C\C(O)=O | ||
| Formula | C19H17ClFN5S.C4H4O4 | M.Wt | 517.96 |
| Solubility | Soluble in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9307 mL | 9.6533 mL | 19.3065 mL |
| 5 mM | 0.3861 mL | 1.9307 mL | 3.8613 mL |
| 10 mM | 0.1931 mL | 0.9653 mL | 1.9307 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 33 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *